A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV

A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV

The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV).

The main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment？ Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.

Inclusion Criteria:

• Recent history of miscarriage or delivery (within the past 8 weeks)
• Strong willingness to undergo conservative management
• Hemodynamically stable
• Signed informed consent form

Exclusion Criteria:

• Heavy vaginal bleeding (requiring immediate surgical intervention)
• Active pelvic or systemic infection (e.g., fever >38°C, elevated CRP/WBC)
• Severe dysfunction of vital organs (heart, liver, or kidney)
• Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance)
• Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels)
• Placenta accreta spectrum disorders diagnosed during current pregnancy
• History of uterine artery embolization